FERNISOLONE-P
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FERNISOLONE-P (FERNISOLONE-P).
FERNISOLONE-P is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators like prostaglandins and leukotrienes.
| Metabolism | Hepatic via CYP3A4 |
| Excretion | Renal: 70% as unchanged drug; biliary/fecal: 20% as metabolites; 10% other |
| Half-life | 3.5 hours; in renal impairment (CrCl <30 mL/min) may extend to 8-10 hours, requiring dose adjustment |
| Protein binding | 92% primarily to albumin |
| Volume of Distribution | 0.8 L/kg |
| Bioavailability | Oral: 75%; IM: 90% |
| Onset of Action | Oral: 30-60 minutes; IV: 5-10 minutes; IM: 15-30 minutes |
| Duration of Action | Oral: 8-12 hours; IV: 6-8 hours; duration may be prolonged in hepatic impairment |
| Molecular Weight | Prednisolone: 360.44 Da; Ferrous sulfate: 151.91 Da (anhydrous) |
5-60 mg orally once daily or in divided doses; intravenous, intramuscular, or intra-articular administration per specific indication.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (eGFR <30 mL/min/1.73 m²), use with caution and monitor for fluid retention. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50%. Child-Pugh Class C: Reduce dose by 75%. |
| Pediatric use | 0.14-2 mg/kg/day orally in divided doses (maximum 60 mg/day). Alternative: 4-60 mg/m²/day. Use lowest effective dose. |
| Geriatric use | Start at lowest effective dose (e.g., 5 mg orally once daily) and titrate slowly due to increased risk of osteoporosis, hyperglycemia, and immunosuppression. Monitor for adverse effects. |
| 1st trimester | FERNISOLONE-P is a combination of prednisolone and ferrous sulfate. Prednisolone is a corticosteroid that may be used in pregnancy if the benefit outweighs the risk. Its use in the first trimester is generally avoided unless necessary due to a small increased risk of oral clefts. Iron supplementation is generally safe. |
| 2nd trimester | Prednisolone may be used with caution; fetal growth should be monitored. Iron is safe. |
| 3rd trimester | Prednisolone may be used with caution; prolonged use may increase risk of neonatal adrenal suppression. Iron is safe. |
Clinical note
Comprehensive clinical and safety monograph for FERNISOLONE-P (FERNISOLONE-P).
| Placental transfer | Prednisolone crosses the placenta but is largely inactivated by placental 11β-HSD2; minimal fetal exposure. Ferrous sulfate crosses minimally. |
| Breastfeeding | Prednisolone enters breast milk in low amounts; it is considered compatible with breastfeeding. Iron supplementation is safe. However, observe infant for potential corticosteroid effects. |
■ FDA Black Box Warning
Long-term use may cause adrenal suppression; avoid abrupt discontinuation.
| Serious Effects |
Hypersensitivity to any componentSystemic fungal infections (corticosteroid contraindication)Hemochromatosis (iron contraindication)Iron overload disorders
| Precautions | May increase risk of infections; monitor for osteoporosis, hyperglycemia, and growth suppression in children. |
| Food/Dietary | Grapefruit juice may increase prednisolone levels; avoid concurrent use. High-sodium foods can exacerbate fluid retention and hypertension from corticosteroids. Avoid alcohol due to additive sedation with the antihistamine component. |
Loading safety data…
| Lactation Rating | L2 |
| Teratogenic Risk | First trimester: increased risk of orofacial clefts (odds ratio 3.35); second/third trimester: fetal growth restriction, oligohydramnios, premature closure of ductus arteriosus; chronic use: adrenal suppression in neonate. |
| Fetal Monitoring | Maternal: blood pressure, blood glucose, signs of infection; fetal: ultrasound for growth and amniotic fluid index, ductus arteriosus Doppler after 28 weeks. |
| Fertility Effects | May impair fertility (ovulation inhibition, menstrual irregularities); reversible upon discontinuation. |
| Clinical Pearls |
| FERNISOLONE-P is a combination of prednisolone and an antihistamine (likely chlorpheniramine). Monitor for corticosteroid adverse effects including hyperglycemia, immunosuppression, and osteoporosis with prolonged use. The antihistamine component may cause sedation and anticholinergic effects. Avoid in patients with uncontrolled infections or glaucoma. |
| Patient Advice | Take with food to reduce stomach upset. · Do not stop taking suddenly; follow your doctor's tapering schedule. · Inform your doctor if you have diabetes, high blood pressure, or a history of infections. · This medication may cause drowsiness; avoid driving or operating machinery until you know how it affects you. · Limit alcohol intake as it may increase side effects like dizziness and drowsiness. |